Novavax Inc (NASDAQ:NVAX)

Data as of Oct 23
 +0.14 / +2.89%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Novavax, Inc. is a clinical-stage biopharmaceutical company, which engages in development of novel recombinant vaccines to address a broad range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Its product pipeline targets a variety of infectious diseases and currently has completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and Respiratory Syncytial Virus. Novavax was founded in 1987 and is headquartered in Gaithersburg, MD.

Contact Information

Novavax, Inc.
20 Firstfield Road
Gaithersburg Maryland 20878
P:(240) 268-2000
Investor Relations:



Individual stakeholders7.06%
Mutual fund holders34.49%
Other institutional23.09%

Top Executives

Stanley C. ErckPresident, Chief Executive Officer & Director
Barclay A. PhillipsChief Financial Officer, Treasurer & Senior VP
Gregory M. GlennSenior Vice President-Research & Development
Louis F. FriesChief Medical Officer & Vice President
John A. HerrmannSecretary, Senior Vice President & General Counsel

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.